OneWorld Health selects Odyssey Research for phase 4 study in India
SAN FRANCISCO, USA / NEW DELHI, INDIA March 28, 2007 -- The Institute for OneWorld Health, a US-based non-profit pharmaceutical company that develops drugs for people with neglected diseases in the developing world, today announced the selection of Odyssey Research, a Bismarck, North Dakota-based clinical trial management organization (TMO) with offices in New Delhi, India, to support its upco...Institute for OneWorld Health hosts global health seminar at AAAS Annual Meeting
... "Once viewed as too costly, sc...Institute for OneWorld Health awarded $46 million grant to combat diarrheal disease
... Diarrheal diseases are a leading cause of death in children under t...Institute for OneWorld Health hosts panels at ASTMH
... ... Rising to the Challenge: A discussion of successful strategies for conducting clinical trials in developi...Institute for OneWorld Health to exhibit at BIO
Representatives from the Institute for OneWorld Health, the first nonprofit pharmaceutical company in the U.S., will be available at the BIO 2005 Annual International Convention to discuss how the biotechnology industry can partner in the company's innovative approaches to develop safe, effective and affordable new medicines for people with infectious disease in developing countries....... Th...OneWorld Health drug receives 'Orphan' designation from U.S. and European regulatory agencies
San Francisco, Calif. May 23, 2005 The Institute for OneWorld Health, the first nonprofit pharmaceutical company in the U.S., announced today it has received Orphan Drug Designation from the two leading regulatory agencies in the world, the Food and Drug Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA), for paromomycin to treat visceral leishmaniasis (...OneWorld Health awarded Sapling Foundation grant
San Francisco, Calif. May 3, 2005 The Institute for OneWorld Health, the first nonprofit pharmaceutical company in the U.S., today announced it received a grant from the Sapling Foundation (Woodside, Calif.) to further engage the pharmaceutical industry in global health partnerships to benefit developing countries. This is the second such grant from the Foundation in support of fostering colla...OneWorld Health receives multimillion dollar grant for next steps in control of deadly disease
San Francisco, Calif. April 14, 2005 The Institute for OneWorld Health, the first nonprofit pharmaceutical company in the U.S., today announced that it has received a grant of nearly US$10 million from the Bill & Melinda Gates Foundation to continue advancing its promising drug for visceral leishmaniasis (VL), paromomycin, through the approval and post-approval process. Specifically, the compan...Institute for OneWorld Health CEO speaks at 2005 World Life Sciences Forum, BioVision
Victoria Hale, Ph.D., CEO and Founder of the Institute for OneWorld Health will provide perspectives on drug and vaccine development from a nonprofit pharmaceutical company's viewpoint at two events at BioVision. The biannual event of the World Life Sciences Forum fosters debate and exchange among representatives from science, society, and industry. OneWorld Health will also exhibit at BioVisi...Institute for OneWorld Health awarded Skoll Foundation's Social Entrepreneurship Award
San Francisco, Calif. March 21, 2005 The Institute for OneWorld Health today announced that it has been awarded a 2005 Skoll Award for Social Entrepreneurship in the amount of $615,000 over three years. Based in San Francisco, OneWorld Health is the first nonprofit pharmaceutical company in the U.S. and develops new medicines to cure infectious diseases that disproportionately affect the poores...OneWorld Health named business leader in public health on '2004 Scientific American 50'
San Francisco, Calif. Nov. 8, 2004 The Institute for OneWorld Health has been selected by the Board of Editors at Scientific American magazine as the Business Leader in Public Health and Epidemiology for creating the first nonprofit U.S. drug firm that seeks to develop new, affordable medicines for people in the developing world. In recognition, OneWorld Health will be included in the Scientif...OneWorld Health presents preliminary clinical trial results at ASTMH
The initial results of a Phase III clinical trial in India for a low-cost drug to cure a deadly parasitic disease will be presented by Victoria Hale, Ph.D., founder and CEO of the Institute for OneWorld Health, the first nonprofit pharmaceutical company in the U.S. The results will be made at the American Society of Tropical Medicine and Hygiene conference to be held Nov. 7-11 at the Fontaineble...